Back to Browse Journals » Pharmacogenomics and Personalized Medicine » Volume 6

Copy number variation in sulfotransferase isoform 1A1 (SULT1A1) is significantly associated with enzymatic activity in Japanese subjects

Authors Yu X, Kubota T, Dhakal I, Hasegawa S, Williams S, Ozawa S, Kadlubar S

Published Date March 2013 Volume 2013:6 Pages 19—24

DOI http://dx.doi.org/10.2147/PGPM.S36579

Received 1 August 2012, Accepted 24 September 2012, Published 6 March 2013

Xinfeng Yu,1 Takahiro Kubota,2 Ishwori Dhakal,1 Setsuo Hasegawa,3 Suzanne Williams,1 Shogo Ozawa,4 Susan Kadlubar1

1Division of Medical Genetics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA; 2Chiba Institute of Science, Chiba, Japan; 3Sekino Clinical Pharmacology Clinic, Tokyo, Japan; 4Iwate Medical University, Iwate, Japan

Abstract: Sulfotransferase isoform 1A1 (SULT1A1) plays a key role in the metabolism of a variety of endo- and xenobiotics and it's activity could influence response to drugs. Our previous studies have focused on the impact of genetic variants of SULT1A1 on enzymatic activity in Caucasians and African-Americans. However, the contribution of genetic variants to SULT1A1 activity in Asians has not been explored. In this study, we investigated the collective effects of both SULT1A1 copy number variants (CNVs) and single nucleotide polymorphisms (SNPs) in the promoter region, coding region, and 3´ untranslated region on SULT1A1 activity in Japanese subjects. SNPs in the SULT1A1 promoter and 3´ untranslated region were not associated with SULT1A1 activity (P > 0.05). SULT1A1*1/2 (Arg213His) was marginally associated with SULT1A1 activity (P = 0.037). However, SULT1A1 CNVs were strongly associated with SULT1A1 activity (trend test P = 0.008) and accounted for 10% of the observed variability in activity for Japanese subjects. In conclusion, SULT1A1 CNVs play a pivotal role in determination of SULT1A1 activity in Japanese subjects, highlighting the influence of ethnic differences in SULT1A1 genetic variants on drug metabolism and therapeutic efficacy.

Keywords: CNV, genotype, phenotype, SULT1A1, single nucleotide polymorphisms

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

CYP19A1 single nucleotide polymorphism associations with CYP19A1, NFκB1, and IL6 gene expression in human normal colon and normal liver samples

Penney RB, Lundgreen A, Yao-Borengasser A, Edavana VK, Williams S, Dhakal I, Wolff RK, Kadlubar S, Slattery ML

Pharmacogenomics and Personalized Medicine 2014, 7:163-171

Published Date: 14 July 2014

Lack of correlation between in silico projection of function and quantitative real-time PCR-determined gene expression levels in colon tissue

Penney RB, Lundgreen A, Yao-Borengasser A, Koroth-Edavana V, Williams S, Wolff R, Slattery ML, Kadlubar S

Pharmacogenomics and Personalized Medicine 2013, 6:99-103

Published Date: 9 September 2013

GSTM1 copy number and promoter haplotype as predictors for risk of recurrence and/or second primary tumor in patients with head and neck cancer

Zhang X, Huang M, Wu X, Kadlubar S, Lin J, Yu X, Fan C, Ning B, Kadlubar FF

Pharmacogenomics and Personalized Medicine 2013, 6:9-17

Published Date: 1 March 2013

Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1

Edavana VK, Yu X, Dhakal IB, Williams S, Ning B, Cook IT, Caldwell D, Falany CN, Kadlubar S

Pharmacogenomics and Personalized Medicine 2011, 4:137-145

Published Date: 17 November 2011

Readers of this article also read:

Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen

Chamnanphon M, Pechatanan K, Sirachainan E, Trachu N, Chantratita W, Pasomsub E, Noonpakdee W, Sensorn I, Sukasem C

Pharmacogenomics and Personalized Medicine 2013, 6:37-48

Published Date: 24 May 2013

Non-small-cell lung cancer: molecular targeted therapy and personalized medicine – drug resistance, mechanisms, and strategies

Sechler M, Cizmic AD, Avasarala S, Van Scoyk M, Brzezinski C, Kelley N, Bikkavilli RK, Winn RA

Pharmacogenomics and Personalized Medicine 2013, 6:25-36

Published Date: 4 April 2013

Follow-up analysis of federal process of care data reported from three acute care hospitals in rural Appalachia

Sills ES, Chiriac L, Vaughan D, Jones CA, Salem SA

ClinicoEconomics and Outcomes Research 2013, 5:119-124

Published Date: 27 March 2013

GSTM1 copy number and promoter haplotype as predictors for risk of recurrence and/or second primary tumor in patients with head and neck cancer

Zhang X, Huang M, Wu X, Kadlubar S, Lin J, Yu X, Fan C, Ning B, Kadlubar FF

Pharmacogenomics and Personalized Medicine 2013, 6:9-17

Published Date: 1 March 2013

Pharmacogenomic considerations in opioid analgesia. [Corrigendum]

Vuilleumier PH, Stamer UM, Landau R

Pharmacogenomics and Personalized Medicine 2013, 6:1-2

Published Date: 14 January 2013

Importance of pharmacogenetics in the treatment of children with attention deficit hyperactive disorder: a case report

Tan-kam T, Suthisisang C, Pavasuthipaisit C, Limsila P, Puangpetch A, Sukasem C

Pharmacogenomics and Personalized Medicine 2013, 6:3-7

Published Date: 11 January 2013

CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients

Sirachainan E, Jaruhathai S, Trachu N, Panvichian R, Sirisinha T, Ativitavas T, Ratanatharathorn V, Chamnanphon M, Sukasem C

Pharmacogenomics and Personalized Medicine 2012, 5:149-153

Published Date: 17 October 2012

Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1

Edavana VK, Yu X, Dhakal IB, Williams S, Ning B, Cook IT, Caldwell D, Falany CN, Kadlubar S

Pharmacogenomics and Personalized Medicine 2011, 4:137-145

Published Date: 17 November 2011